Natalizumab (NZ), a humanized anti-α4 integrin monoclonal antibody, is used in the treatment of highly active multiple sclerosis (MS). Progressive multifocal leukoencephalopathy (PML) and rare cases of primary CNS lymphoma1 have been reported in NZ-treated patients, whereas severe relapses with MS reactivation are described after NZ discontinuation.
No takes yet. Share an insight, caveat, or question.
Debs et al. (2015) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: